Poolbeg Pharma and CytoReason identify “very exciting influenza targets”
–News Direct–
Poolbeg Pharma PLC (AIM:POLB, OTCQB:POLBF) CEO Jeremy Skillington and CytoReason co-founder and CEO David Harel speak to Thomas Warner from Proactive after announcing what they call a "significant breakthrough" in their world-first influenza Artificial Intelligence ('AI') Programme. Skillington says that the collaboration has yielded some "very exciting influenza targets" and that Poolbeg will now be "actively exploring the most effective way to bring them forward into development." He also highlights Poolbeg's RSV-focused AI collaboration with CytoReason that concluded in 2022, saying that Poolbeg "is now working on validating those targets… and will have data before the end of the year."
Contact Details
Proactive UK Ltd
+44 20 7989 0813
View source version on newsdirect.com: https://newsdirect.com/news/poolbeg-pharma-and-cytoreason-identify-very-exciting-influenza-targets-850721061
Poolbeg Pharma PLC
COMTEX_436158282/2655/2023-06-29T03:54:24